Novartis in Singapore continues to monitor the coronavirus (COVID-19) closely. Our focus is to ensure the health and safety of our people, the healthcare professionals we engage with daily, and to ensure the supply of our medicines to patients.
Currently, we do not anticipate any supply chain disruption. We expect that our existing stock is sufficient to cover production and distribution needs for the time being. We have solid processes in place to mitigate the risk of shortages, including safety stocks, dual sourcing and business continuity plans (as applicable).
Following the COVID-19 Circuit Breaker announcement by the Singapore government, our Singapore and Regional Headquarter office workplace premise at Mapletree Business City will be closed from 7 April 2020 - 1 June 2020. Our office associates are now working remotely and have been strongly encouraged to stay at home. Both of our pharmaceutical manufacturing sites at Tuas Biomedical Park are in operation and will remain open with strict measures on safe distancing and split team arrangements.
We have also suspended face-to-face engagement with healthcare professionals until further notice. Our associates are utilizing phone and virtual options as necessary.
We have implemented the above measures to protect the health of our associates and the wider communities, including healthcare professionals and the patients we serve.
Globally, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus pandemic, including:
a Novartis COVID-19 Response Fund will provide USD 20 million to support communities around the world most impacted by the coronavirus pandemic.
partnering with multi-stakeholder external consortia, including the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome Trust and MasterCard.
committing to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response.
Sandoz, the Novartis generics and biosimilars division, is maintaining prices on a basket of essential medicines that may help in the treatment of COVID-19.
assessing whether Novartis medicines could be repurposed to treat patients with coronavirus infection.
Novartis remains responsive to any developments regarding coronavirus and will take all necessary steps to protect our associates, healthcare professionals and patients. We will continue to monitor the situation closely and adapt our measures as the situation evolves.